Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna allogeneic HCT Coverage & Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0674

    Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia

    Customize your policy alerts

    Sign up for Aetna Policy 0674 alerts

    Get alerted when Policy 0674 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for hematopoietic cell transplantation (HCT) in members with chronic myelogenous leukemia (CML), including medical necessity criteria for allogeneic transplants and the noncoverage stance for autologous transplants. Applies to patients being considered for HCT for CML.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
    Policy CodePolicy 0674
    Change TypeNo material change
    Effective DateNov 21, 2003
    Last ReviewSep 19, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization and document that the member meets the transplanting institution's written eligibility criteria or has failed, is resistant to, or is intolerant of tyrosine kinase inhibitors before allogeneic HCT.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    coveredAllogeneic coverage
    not coveredAutologous stance
    38205,38230,38240,38242Example CPTs
    C92.10-C92.11ICD-10 range
    NCCN/CCOGuideline notes

    Coverage Criteria

    Medical Necessity for Allogeneic HCT

    Allogeneic hematopoietic cell transplantation is covered when the following guideline is met:

    Allogeneic transplant coverage condition: Member meets the transplanting institution's written eligibility criteria; if the transplanting institution has no written eligibility criteria, the member has failed to respond to, developed resistance to, or is intolerant to tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) and does not have serious organ dysfunction per the transplanting institution's evaluation.

    From policy medical necessity statement

    Autologous HCT — Not Covered

    Autologous HCT coverage: Autologous hematopoietic cell transplantation (auto BM/PSCT) is considered experimental and investigational for the treatment of CML under all circumstances because its effectiveness for this indication has not been established.

    Not covered for CML

    Aetna considers autologous hematopoietic cell transplantation (auto BM/PSCT) for chronic myelogenous leukemia to be experimental and investigational under all circumstances because its effectiveness for this indication has not been established.

    Clinical practice guidelines and evidence summaries do not support routine use of autologous stem cell transplantation for CML. The National Comprehensive Cancer Network’s CML guidance (2009) and recent reviews do not discuss auto‑SCT as a standard treatment option, a meta‑analysis of randomized trials did not find a role for auto‑SCT in initial therapy, and Cancer Care Ontario guidelines state that autologous stem cell transplantation is not recommended for patients with CML.

    Candidate Criteria for Allogeneic HCT

    Candidate criteria for allo-HCT

    When institutional criteria are absent, candidates for allogeneic HCT are typically those who:

    Candidate criteria: Have failed to respond to, are resistant to, or are intolerant of tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib); OR have disease progression to accelerated or blast phase after TKI therapy or high-risk features following TKI therapy; OR are younger patients manifesting resistance to second-line TKI therapy with an appropriate donor available.

    Combined policy guidance and cohort study findings

    Allo-HSCT candidate considerations

    Factors identified in the literature that influence consideration for allo-HSCT in CML:

    General candidate factors: Consider allo-HSCT for younger patients with chronic-phase CML who are resistant to second-line TKI therapy or after failure of multiple TKIs; disease status at transplantation and patient age are important prognostic factors.

    Derived from cohort analyses noting adverse outcomes with multiple prior TKIs.

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for listed transplant-related CPT/HCPCS codes when the member meets selection criteria for allogeneic hematopoietic cell transplantation. Ensure prior auth is obtained when institutional eligibility is met or when documentation shows failure, resistance, or intolerance to TKIs and allogeneic transplant is being requested.

    • Prior authorization required when selection criteria for allogeneic HCT are met
    • Affected codes include CPT 38205, 38230, 38240, 38242 and HCPCS S2150
    Documentation Required

    Pre-transplant TKI Exposure Risk

    Document prior TKI therapy in the medical record. Note that use of three prior TKIs before transplant has been associated with higher non-relapse mortality and worse prognosis; this may influence authorization decisions.

    • Prior exposure to 1, 2, or 3 TKIs should be recorded

    Pre-Transplant Evaluation Requirements

    Documentation Required

    Document TKI failure/resistance/intolerance and institutional organ‑function evaluation

    Document failure, resistance, or intolerance to imatinib, dasatinib, or nilotinib if the transplanting institution lacks written eligibility criteria; the institution must also evaluate and document serious organ dysfunction status.

    • Provide documentation of TKI failure/resistance/intolerance when institutional criteria are absent.
    • Include the transplanting institution's evaluation of organ dysfunction (absence of serious organ dysfunction required when institutional criteria absent).
    Documentation Required

    Document TKI treatment history when no institutional criteria exist

    If the transplanting institution has no written eligibility criteria, explicitly document attempts and outcomes with TKIs (failure, resistance, or intolerance) as part of the evaluation for allo‑HCT candidacy.

    • Ensure records show TKI treatment history and documented failure/resistance/intolerance where institutional criteria are lacking.

    Coding

    Covered CPT Codes (if selection criteria met)CPTCovered
    38205Blood-derived hematopoietic cell harvesting for transplantation, per collection; allogeneic.
    38230Bone marrow harvesting for transplantation; allogenic.
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
    38242Allogeneic lymphocyte infusions.
    CPT Codes Not Covered for CML IndicationCPTNot Covered
    38206Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
    38232Bone marrow harvesting for transplantation; autologus.
    38241Hematopoietic progenitor cell (HPC); autologous transplantation.
    Other related CPT CodesCPT
    38204-38215Bone Marrow or Stem Cell Services/Procedures.
    HCPCS CodesHCPCS
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition.
    S0088Imatinib, 100mg.
    ICD-10 CodesICD-10
    C92.10Chronic myeloid leukemia, BCR/ABL-positive, chronic phase
    C92.11Chronic myeloid leukemia, BCR/ABL-positive, accelerated phase
    Coding — thresholds (placeholder)
    ThresholdsN/A
    NotesNo numerical or clinical thresholds specified in the coding section of this policy.
    Related code groupsSee covered and not-covered CPT/HCPCS groups for applicability.

    Contraindications

    When institutional eligibility criteria are not available, the policy requires documentation that the transplanting institution evaluated the member and found no serious organ dysfunction. Serious organ dysfunction as defined by the transplanting institution is a consideration against proceeding with hematopoietic cell transplantation and must be absent for the member to meet the policy’s medical necessity conditions for allogeneic HCT.

    The policy does not list specific absolute contraindications to transplantation. However, because available evidence and guidelines do not establish benefit for autologous transplantation in CML, autologous HCT is not recommended and is considered investigational for this indication; autologous transplant codes are therefore not an endorsed treatment option for CML under this policy.

    Center Requirements

    Documentation Required

    Provide transplanting institution's written eligibility criteria and organ‑function evaluation

    Obtain and document the transplanting institution's written eligibility criteria; when submitting authorization requests, confirm the institution has evaluated the member for serious organ dysfunction per its protocols.

    • Transplanting institution's written eligibility criteria are required.
    • Transplant center must evaluate for serious organ dysfunction and documentation of that evaluation should be included.

    Post-Transplant Coverage

    Donor lymphocyte infusion and post-allo maintenance
    Post-allo optionsDonor lymphocyte infusion (DLI) is an option for molecular relapse after allogeneic stem cell transplantation.
    Maintenance therapiesPreventive post-allo measures such as interferon alpha or imatinib may be beneficial for patients at high predicted risk of recurrence.
    Evidence on timingStudy of 155 relapsed patients showed overall survival 76% at 5 years after lymphocyte infusions; timing (beyond 6 months vs within 6 months) influenced outcomes.
    Donor effectOutcomes after DLI were better with sibling donors than unrelated donors in reported series.

    Definitions

    Philadelphia (Ph) chromosome / BCR-ABL
    DefinitionPhiladelphia (Ph) chromosome: a reciprocal balanced translocation between the long arms of chromosomes 9 and 22 producing the BCR–ABL fusion gene (p210BCR–ABL) with constitutive tyrosine kinase activity.
    PrevalenceThe Ph can be detected in about 95% of patients with CML.
    Clinical significanceBCR–ABL fusion drives CML pathogenesis and is the molecular target for tyrosine kinase inhibitors.
    Allogeneic BM/PSCT (allo-BMT / allo-HSCT)
    DefinitionAllogeneic BM/PSCT (allo-BMT / allo-HSCT): hematopoietic stem cell transplantation using donor (allogeneic) bone marrow or peripheral stem cells; considered the only potentially curative therapy for CML.
    Indication timingMost effective when carried out during chronic phase of disease; historically offered early in chronic phase prior to progression.

    Background

    Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm driven by the BCR‑ABL (Philadelphia) fusion, a reciprocal translocation between chromosomes 9 and 22 that produces a constitutively active tyrosine kinase. CML most often presents in a chronic phase that can progress to accelerated or blast phase. Tyrosine kinase inhibitors (e.g., imatinib) are first‑line therapy and have markedly improved outcomes; allogeneic hematopoietic cell transplantation remains the only potentially curative option and is generally reserved for patients with progression or failure of TKI therapy.

    Policy Summary
    PayerAetna
    PolicyHematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
    Policy CodePolicy 0674
    Change TypeNo material change
    Effective DateNov 21, 2003
    Last ReviewSep 19, 2023
    Next Review DateJul 25, 2024
    Key ActionObtain prior authorization and document that the member meets the transplanting institution's written eligibility criteria or has failed, is resistant to, or is intolerant of tyrosine kinase inhibitors before allogeneic HCT.
    SourceLink
    On This Page
    Coverage CriteriaCandidate Criteria for Allogeneic HCTProvider Actions and AuthorizationPre-Transplant Evaluation RequirementsCodingContraindicationsCenter RequirementsPost-Transplant CoverageDefinitionsBackground
    Risk factors affecting outcomes: Use of three TKIs prior to transplantation, presence of chronic graft-versus-host disease, and conditioning regimen (e.g., busulfan/cyclophosphamide versus total body irradiation/cyclophosphamide) have been associated with differences in non-relapse and overall mortality and should factor into consideration.

    From cohort and survivor studies

  1. Use of 3 TKIs prior to transplant is a documented adverse prognostic factor
  2. Documentation Required

    Comorbidity Scoring (HCT-CI)

    Providers should document comorbidity assessment using a validated tool such as the Hematopoietic Cell Transplantation–Specific Comorbidity Index (HCT-CI). Include the calculated HCT-CI score with the authorization request to support clinical risk evaluation.

    • Include HCT-CI score in authorization documentation
    • Reference: Hematopoietic Cell Transplantation–Specific Comorbidity Index (HCT-CI)
    Documentation Required

    Document TKI Failure or Institutional Eligibility

    Include documentation that the member meets the transplanting institution's written eligibility criteria. If institutional criteria are not available, provide documentation of failure, resistance, or intolerance to tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) to support medical necessity for allogeneic HCT.

    • Attach transplanting institution written eligibility criteria when available
    • If no institutional criteria, document TKI failure/resistance/intolerance to imatinib, dasatinib, nilotinib
    Documentation Required

    TKI Therapy Before Transplant

    Tyrosine kinase inhibitor (TKI) therapy is the standard first-line treatment for CML. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is generally reserved for patients with disease progression or treatment failure after multiple TKIs. Authorization decisions should reflect prior TKI use and treatment history.

    • TKIs are first-line; allo-HSCT considered for progression or failure after multiple TKIs
    • Document prior lines of TKI therapy and reasons for discontinuation
    Step Therapy

    Step Therapy Requirements

    There are no formal step therapy requirements specified in this policy section beyond documenting prior TKI use and failure/intolerance when applicable. Treat this as informational for authorization reviewers and providers.

    • No specific step-therapy sequencing beyond standard practice (document prior TKI attempts)
    Note

    Supplemental Aetna Resources

    Supplemental Aetna resources and external links (glossary, mobile app, program provisions, and notices) may be referenced for member and provider information. Note that external links are provided for convenience and Aetna is not responsible for their content.

    • Glossary, Aetna Mobile App, Program Provisions and Notices available via Aetna website
    • External site content disclaimer applies
    Documentation Required

    Include HCT‑CI comorbidity assessment in evaluation documentation

    Include assessment using the Hematopoietic Cell Transplantation‑Specific Comorbidity Index (HCT‑CI) as part of the pre‑transplant evaluation and documentation.

    • HCT‑CI calculator is specifically referenced in the appendix as an assessment tool to evaluate comorbidity burden pre‑transplant.
    Risk/benefitAllo transplant carries significant morbidity and mortality compared with medical therapy; donor availability and patient fitness guide selection.
    allo-HSCT / Allogeneic BM/PSCT
    DefinitionAllo-HSCT / Allogeneic BM/PSCT: transplantation using donor-derived hematopoietic cells for CML patients, generally reserved for those with progression or failure of multiple TKIs.
    Candidate considerationsConsider for younger patients with chronic-phase CML who are resistant to second-line TKI therapy or after failure of multiple TKIs.
    Prognostic factorsDisease status at transplantation, patient age, and number of prior TKIs (use of 3 TKIs associated with higher non-relapse mortality) influence outcomes.
    auto-BM/PSCT / Autologous transplantation
    DefinitionAutologous BM/PSCT / Autologous transplantation: transplantation using the patient’s own bone marrow or peripheral stem cells.
    Evidence summaryAvailable evidence has not established auto-BM/PSCT as an effective treatment for CML; studies are heterogeneous and largely predate imatinib.
    Guideline stanceGuidelines (NCCN 2009, Cancer Care Ontario 2009) do not recommend autologous stem cell transplantation for routine treatment of CML; it is considered investigative/experimental.